



Fri 2 September
12:00pm – 1:00pm
AEST

What does a new drug commercialisation pathway entail?

<https://www.eventbrite.com.au/e/240635064957>

We are delighted to welcome Dr David Fuller, internationally experienced biopharmaceutical executive, to provide essential insights on what a new drug commercialisation pathway actually entails. This webinar will cover:

- Defining a commercial product versus an idea
- Starting with the end in mind
- IP considerations
- Clinical indication(s)
- Regulatory aspects
- Defining your target market
- Key value-adding steps

Reservations are handled by Eventbrite, with the webinar itself delivered via Zoom. Simply head along to the Eventbrite link and fill in your details, using your University email address. You will be registered and sent details of how to join the webinar from the Eventbrite Online Event page for that webinar.

Meet your Presenter:



Dr David Fuller

David Fuller is currently Chief Medical Officer, Race Oncology and Chairman of EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta (ASX: 1AD). He has more than 30 years of R&D experience, spanning large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.

Most recently Dr Fuller was the Senior Vice President of Clinical Development in the Oncology Business Unit at Syneos Health Clinical Solutions. Prior to this he was a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe.